These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 24328429)

  • 1. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
    Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
    Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
    Barnett AH
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
    Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
    Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
    Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
    Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
    J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
    Prescrire Int; 2013 May; 22(138):121. PubMed ID: 23819170
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study.
    Mahar SA; Hasan MI; Khan MI; Fawwad A; Hussain S; Maheshwary N; Kumar K; Siddiqi A; Khan MA
    J Pak Med Assoc; 2014 Nov; 64(11):1297-302. PubMed ID: 25831650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
    Prasanna Kumar KM; Phadke U; Brath H; Gawai A; Paldánius PM; Mathieu C
    Prim Care Diabetes; 2016 Dec; 10(6):452-458. PubMed ID: 27353459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
    Bolli G; Dotta F; Colin L; Minic B; Goodman M
    Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
    Haluzík M; Veselá V; Gerle J; Brada M; Dohnalová L; Edelsberger T; Houdová J
    Vnitr Lek; 2013 Dec; 59(12):1049-56. PubMed ID: 24350936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A; Dejager S; Bosi E
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
    Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
    Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study.
    Ji LN; Pan CY; Lu JM; Li H; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Zhang RY; Wang XL; Wang L;
    Cardiovasc Diabetol; 2013 Aug; 12():118. PubMed ID: 23958390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.